Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT06081101

Ketorolac Versus Corticosteroid Injections for Sacroiliac Joint Pain

Conditions: Sacro-iliac Joint Pain

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: EARLY_PHASE1
Enrollment: 20
Sponsor: McMaster University

Location: Michael G. DeGroote Pain Clinic Hamilton Ontario

Summary

This study will contribute to the current literature that have compared joint injections with steroid versus ketorolac providing evidence for the use of ketorolac for SI joint pain. Currently steroid is the clinical standard for joint injections, however with repetitive use, steroid injections can damage the joint. Ketorolac is an alternative anti-inflammatory medication that does not cause the same joint damage and at a cheaper cost than steroid. The investigators hypothesize that ultrasound guided SI joint injections utilizing ketorolac provide the same pain relief as corticosteroid SI joint injections measured at 2, 6 and 12 weeks post injection. This would allow more frequent injections to control pain at a decreased cost to the healthcare system.

Eligibility Criteria

Inclusion Criteria: * SI joint pain for at least 3 months * Age greater than 18 * Must have at least 3 special tests positive for SI joint pain on physical exam Exclusion Criteria: * Previous back surgery * Radicular leg pain * Discogenic pain * Myofascial pain syndrome * Depression * Systemic infection or localized infection at anticipated needle entry sites * Cognitive impairment preventing informed consent or accurate collection of data * Patient allergic to medication used * NSAID contraindications including: * Gastrointestinal bleeds * Renal failure * Symptomatic congestive heart failure * Cirrhosis

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06081101). StuddyBuddy aggregates publicly available trial information.